111th Day Of Lockdown

Maharashtra25442714032510289 Tamil Nadu138470895321966 Delhi112494899683371 Gujarat41906291982046 Karnataka3884315411686 Uttar Pradesh3647623334934 Telangana3467122482356 West Bengal3001318581932 Andhra Pradesh2916815412328 Rajasthan2439218103510 Haryana2124015983301 Madhya Pradesh1763212876653 Assam168071089541 Bihar1630511953125 Odisha13737875091 Jammu and Kashmir105135979179 Kerala7874409532 Punjab78215392199 Chhatisgarh4081315319 Jharkhand3760230831 Uttarakhand3537278647 Goa2453120714 Tripura206714212 Manipur16098960 Puducherry141873918 Himachal Pradesh121391610 Nagaland8453270 Chandigarh5594178 Arunachal Pradesh3601382 Meghalaya295452 Mizoram2311500 Sikkim164810
Business Companies 05 Jun 2020 Sun Pharma begins ph ...

Sun Pharma begins phase-2 trial on AQCH, a potential COVID-19 drug

Published Jun 5, 2020, 2:59 pm IST
Updated Jun 5, 2020, 2:59 pm IST
The company received approval from Drugs Controller General of India for conducting the trials of phytopharmaceutical drug in April
Sun Pharma initiates phase-2 clinical trials for potential COVID-19 treatment drug. (PTI Photo)
 Sun Pharma initiates phase-2 clinical trials for potential COVID-19 treatment drug. (PTI Photo)

New Delhi: Drug major Sun Pharmaceutical Industries on Friday said it has commenced phase-2 clinical trials on AQCH, a plant-derived drug, for potential treatment of COVID-19.

The company received approval from the Drugs Controller General of India (DCGI) for conducting the trials of the phytopharmaceutical drug in April this year, Sun Pharma said in a statement.


"The clinical trials will be conducted across 12 centres in India on 210 patients. The treatment duration for patients will be 10 days. The results of the clinical trials are expected by October 2020," it added.

Human safety study of AQCH has already been completed and the drug has been found safe at the recommended dose for phase-2 study, Sun Pharma said.

"This is the first phytopharmaceutical drug approved for clinical trials by the DCGI as a potential treatment for COVID-19. AQCH has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with ICGEB, Italy," Sun Pharma MD Dilip Shanghvi said.


These results combined with information on mechanism of action through in-vitro and small animal studies give us the confidence to evaluate this potential treatment option for COVID-19 patients, he added.

AQCH, which is being developed for dengue, has shown broad antiviral effect in in vitro studies and hence is being tested as a potential treatment option for COVID-19, Sun Pharma said.

"Our efforts to develop a safe, effective and affordable drug against dengue started about 13 years ago. The collaborating team quickly initiated studies for the development of a drug against COVID-19," Department of Biotechnology Secretary Renu Swarup said.


Stating that Council of Scientific and Industrial Research (CSIR) has had a close association with the Indian pharma industry, CSIR DG Shekhar C Mande said the council “welcomes this collaboration with Sun Pharma in taking forward AQCH into clinical trials for COVID-19 patients. This collaboration aligns with our scientific rationale for the quickest way to develop drugs against SARS-CoV-2".

Shares of Sun Pharmaceutical Industries were trading at Rs 504.15 per scrip on BSE, up 1.67 per cent from their previous close.

Location: India, Delhi, New Delhi